This study is being done to test the safety and efficacy of the study drug LY3852710 for the treatment of diabetic peripheral neuropathic pain.
1 Primary · 6 Secondary · Reporting Duration: Baseline, Up to Week 8
Experimental Treatment
Non-Treatment Group
125 Total Participants · 2 Treatment Groups
Primary Treatment: LY3852710 · Has Placebo Group · Phase 2
Age 18+ · All Participants · 4 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Nevada | 50.0% |
Georgia | 50.0% |
Met criteria | 50.0% |
Did not meet criteria | 50.0% |
Artemis Institute for Clinical Research | 100.0% |
0 | 100.0% |